HazemYacoub
@hazemyacoub.bsky.social
Oral solid dosage forms are still going strong, with demand for OSD oncology CDMOs continuing to rise.
The continued demand for home-based care will continue to fuel the need for oral dosage forms, and it's CDMOs that are helping pharma companies keep up as technology and regulation evolve.
The continued demand for home-based care will continue to fuel the need for oral dosage forms, and it's CDMOs that are helping pharma companies keep up as technology and regulation evolve.
Oral Solid Dose Oncology CDMO Market Size, Report by 2034
The global oral solid dose oncology CDMO market is growing with rising demand for outsourced cancer drug manufacturing and advanced solid dosage formulation.
www.precedenceresearch.com
November 12, 2025 at 8:22 AM
Oral solid dosage forms are still going strong, with demand for OSD oncology CDMOs continuing to rise.
The continued demand for home-based care will continue to fuel the need for oral dosage forms, and it's CDMOs that are helping pharma companies keep up as technology and regulation evolve.
The continued demand for home-based care will continue to fuel the need for oral dosage forms, and it's CDMOs that are helping pharma companies keep up as technology and regulation evolve.
Mobile manufacturing units have the potential to strengthen supply chain flexibility, but are they feasible for oral solid dosages?
The smaller physical footprints of continuous OSD technologies make adapting to mobile manufacturing much simpler than other formulations.
The smaller physical footprints of continuous OSD technologies make adapting to mobile manufacturing much simpler than other formulations.
November 10, 2025 at 6:55 AM
Mobile manufacturing units have the potential to strengthen supply chain flexibility, but are they feasible for oral solid dosages?
The smaller physical footprints of continuous OSD technologies make adapting to mobile manufacturing much simpler than other formulations.
The smaller physical footprints of continuous OSD technologies make adapting to mobile manufacturing much simpler than other formulations.
In continuous manufacturing, changing throughputs often means you need to change machines, but by embracing modular process trains, this issue could soon disappear.
Q&A: Addressing practical challenges in CM
On 10th November at 9:00 AM - 9:30 AM CT, Sarang Oka, scientific fellow, Hovione, will do a talk titled "Addressing Practical Challenges in CM via Novel Hardware and Automation" at PharmSci360 in San Antonio, TX.
pharmaceuticalmanufacturer.media
November 7, 2025 at 7:46 AM
In continuous manufacturing, changing throughputs often means you need to change machines, but by embracing modular process trains, this issue could soon disappear.
India will be one of the earliest markets to face LoE for Semaglutide, but taking advantage will require generics companies to adapt their LoE playbooks.
Source: https://www.iqvia.com/locations/india/blogs/2025/10/semaglutide-loe-in-india-a-rare-opportunity-demanding-a-new-playbook
Source: https://www.iqvia.com/locations/india/blogs/2025/10/semaglutide-loe-in-india-a-rare-opportunity-demanding-a-new-playbook
November 5, 2025 at 9:02 AM
India will be one of the earliest markets to face LoE for Semaglutide, but taking advantage will require generics companies to adapt their LoE playbooks.
Source: https://www.iqvia.com/locations/india/blogs/2025/10/semaglutide-loe-in-india-a-rare-opportunity-demanding-a-new-playbook
Source: https://www.iqvia.com/locations/india/blogs/2025/10/semaglutide-loe-in-india-a-rare-opportunity-demanding-a-new-playbook
Challenging patents can be a powerful way for generics companies to open up the market, but litigation isn't the only approach they can take.
A blend of both litigation and negotiation can help reduce costs and create a degree of certainty that litigation alone cannot provide.
A blend of both litigation and negotiation can help reduce costs and create a degree of certainty that litigation alone cannot provide.
November 3, 2025 at 7:18 AM
Challenging patents can be a powerful way for generics companies to open up the market, but litigation isn't the only approach they can take.
A blend of both litigation and negotiation can help reduce costs and create a degree of certainty that litigation alone cannot provide.
A blend of both litigation and negotiation can help reduce costs and create a degree of certainty that litigation alone cannot provide.
For MENA pharma companies looking to expand beyond their own borders, the EU holds plenty of opportunities.
But these opportunities aren't without complexity. Understanding the different expansion pathways available will help you plan an expansion that fulfils your needs.
But these opportunities aren't without complexity. Understanding the different expansion pathways available will help you plan an expansion that fulfils your needs.
Regulatory Pathways for Pharma Expansion into the EU - Insuvia
Learn how MRP, DCP, and RUP shape EU pharma expansion. Choose the right regulatory pathway to control cost, speed approvals, and reduce risk.
insuvia.com
October 31, 2025 at 8:33 AM
For MENA pharma companies looking to expand beyond their own borders, the EU holds plenty of opportunities.
But these opportunities aren't without complexity. Understanding the different expansion pathways available will help you plan an expansion that fulfils your needs.
But these opportunities aren't without complexity. Understanding the different expansion pathways available will help you plan an expansion that fulfils your needs.
AI-powered drug discovery is rapidly gaining attention, and oral solid dosage forms are leading the segment.
As one of the most commercially viable dosage forms for manufacturers, AI-assisted drug formulation is only going to create more opportunities for manufacturers to grow.
As one of the most commercially viable dosage forms for manufacturers, AI-assisted drug formulation is only going to create more opportunities for manufacturers to grow.
AI-Powered Drug Formulation Market Insights and Analysis
The global AI-powered drug formulation market AI-driven drug formulation enhances healthcare outcomes by optimizing R&D, reducing costs, and accelerating next-generation therapeutic discoveries.
www.precedenceresearch.com
October 29, 2025 at 8:11 AM
AI-powered drug discovery is rapidly gaining attention, and oral solid dosage forms are leading the segment.
As one of the most commercially viable dosage forms for manufacturers, AI-assisted drug formulation is only going to create more opportunities for manufacturers to grow.
As one of the most commercially viable dosage forms for manufacturers, AI-assisted drug formulation is only going to create more opportunities for manufacturers to grow.
Chronic diseases are on the rise in the MENA region, which is fuelling the expansion of clinical trials. With this expansion comes more locally relevant clinical data, allowing drug developers to identify unmet medical needs and explore ways to translate these into pharmaceutical opportunity.
October 29, 2025 at 5:57 AM
Chronic diseases are on the rise in the MENA region, which is fuelling the expansion of clinical trials. With this expansion comes more locally relevant clinical data, allowing drug developers to identify unmet medical needs and explore ways to translate these into pharmaceutical opportunity.
The market for simple oral solids is oversaturated, but there are still plenty of opportunities in more complex OSDs. By perfecting complex generics, manufacturers can escape the intense price pressure traditionally associated with OSDs while still delivering convenient dosage forms for patients.
October 24, 2025 at 7:53 AM
The market for simple oral solids is oversaturated, but there are still plenty of opportunities in more complex OSDs. By perfecting complex generics, manufacturers can escape the intense price pressure traditionally associated with OSDs while still delivering convenient dosage forms for patients.
Infrastructure and a lack of healthcare spending are no longer holding back emerging markets, which accounted for ~40% of pharma revenue growth in 2024. The biggest challenges now will be regulatory variability and supply chain vulnerabilities, but strategic firms can easily navigate these.
Emerging Market to Reach USD 2.92 Trillion by 2034
The global emerging pharmaceutical and healthcare markets are at a transformative inflection point As healthcare systems in Asia Pacific Latin America Africa and the Middle East modernize these regions are no longer peripheral participants in the global health economy they ...
www.openpr.com
October 22, 2025 at 7:43 AM
Infrastructure and a lack of healthcare spending are no longer holding back emerging markets, which accounted for ~40% of pharma revenue growth in 2024. The biggest challenges now will be regulatory variability and supply chain vulnerabilities, but strategic firms can easily navigate these.
Egypt's plans to localize pharma manufacturing aren't just designed to strengthen the nation's pharmaceutical security, but also to position it as a regional leader.
By boosting both pharma infrastructure and investment in talent, Egypt is setting the stage for growth.
By boosting both pharma infrastructure and investment in talent, Egypt is setting the stage for growth.
Egyptian Drug Authority outlines strategy to localize pharma manufacturing - Dailynewsegypt
The Egyptian Drug Authority (EDA) recently held its 16th Board of Directors meeting, led by Ali El-Ghamrawi, Head of the Authority, at its headquarters in the New Administrative Capital. This gathering was part of ongoing efforts to advance Egypt’s pharmaceutical sector, enhance local manufacturing, and bolster the nation’s pharmaceutical security. A key focus of the
www.dailynewsegypt.com
October 20, 2025 at 9:01 AM
Egypt's plans to localize pharma manufacturing aren't just designed to strengthen the nation's pharmaceutical security, but also to position it as a regional leader.
By boosting both pharma infrastructure and investment in talent, Egypt is setting the stage for growth.
By boosting both pharma infrastructure and investment in talent, Egypt is setting the stage for growth.
North American drug manufacturers are using AI to enhance the manufacturing process and boost resilience during a time of uncertainty, which raises the question: could AI be the key to strengthening the global industry against disruption?
October 17, 2025 at 7:41 AM
North American drug manufacturers are using AI to enhance the manufacturing process and boost resilience during a time of uncertainty, which raises the question: could AI be the key to strengthening the global industry against disruption?
In drug manufacturing, control and consistency matter.
But as drugs get more complex, maintaining this using traditional methods becomes more difficult, and companies may find themselves struggling with yield losses.
But AI-enabled digital twins could be the key to eliminating these issues.
But as drugs get more complex, maintaining this using traditional methods becomes more difficult, and companies may find themselves struggling with yield losses.
But AI-enabled digital twins could be the key to eliminating these issues.
October 15, 2025 at 9:00 AM
In drug manufacturing, control and consistency matter.
But as drugs get more complex, maintaining this using traditional methods becomes more difficult, and companies may find themselves struggling with yield losses.
But AI-enabled digital twins could be the key to eliminating these issues.
But as drugs get more complex, maintaining this using traditional methods becomes more difficult, and companies may find themselves struggling with yield losses.
But AI-enabled digital twins could be the key to eliminating these issues.
Despite all the challenges facing the global pharmaceutical sector, there's no doubt that healthcare will always remain a top priority across the globe.
That sentiment is fuelling international expansions into the MENA region, particularly for US firms looking for greater stability.
That sentiment is fuelling international expansions into the MENA region, particularly for US firms looking for greater stability.
From West to East: building biotech bridges across APAC and the Middle East
Amid rising geopolitical uncertainty, US biotech companies are looking beyond tariffs and trade tensions to expand into Asia-Pacific and the Middle East
manufacturingchemist.com
October 13, 2025 at 8:05 AM
Despite all the challenges facing the global pharmaceutical sector, there's no doubt that healthcare will always remain a top priority across the globe.
That sentiment is fuelling international expansions into the MENA region, particularly for US firms looking for greater stability.
That sentiment is fuelling international expansions into the MENA region, particularly for US firms looking for greater stability.
Oral solid dosage forms don't have to be inflexible.
By combining double-dipping, enteric coating, 3D printing, and injection molding, pharma manufacturers can unlock a new level of formulation flexibility and personalization. Make that your competitive advantage.
By combining double-dipping, enteric coating, 3D printing, and injection molding, pharma manufacturers can unlock a new level of formulation flexibility and personalization. Make that your competitive advantage.
Next generation Capsules: Emerging Technologies in Capsule Fabrication and Targeted Oral Drug Delivery
Capsule-based drug delivery has undergone significant advancements, offering enhanced protection for active pharmaceutical ingredients (APIs) and enab…
www.sciencedirect.com
October 10, 2025 at 7:57 AM
Oral solid dosage forms don't have to be inflexible.
By combining double-dipping, enteric coating, 3D printing, and injection molding, pharma manufacturers can unlock a new level of formulation flexibility and personalization. Make that your competitive advantage.
By combining double-dipping, enteric coating, 3D printing, and injection molding, pharma manufacturers can unlock a new level of formulation flexibility and personalization. Make that your competitive advantage.
Solid tablets are popular, but for children, the elderly, and disabled patients, they can be difficult to swallow
Fast-melt tablets are helping to eliminate that problem, and pharma companies that embrace them are finding new opportunities to capture greater market share.
Fast-melt tablets are helping to eliminate that problem, and pharma companies that embrace them are finding new opportunities to capture greater market share.
October 8, 2025 at 9:04 AM
Solid tablets are popular, but for children, the elderly, and disabled patients, they can be difficult to swallow
Fast-melt tablets are helping to eliminate that problem, and pharma companies that embrace them are finding new opportunities to capture greater market share.
Fast-melt tablets are helping to eliminate that problem, and pharma companies that embrace them are finding new opportunities to capture greater market share.
Antitrust action in Europe's pharma industry is heating up, with the European Court of Justice's decision on Teva underlining the importance of getting communication and patent strategies right. MENA-based companies looking to enter the market will benefit from paying close attention.
Antitrust in life sciences—key European developments for pharma companies
We round up the most important recent events in the antitrust space that life sciences companies should be aware of.
www.aoshearman.com
October 6, 2025 at 6:12 AM
Antitrust action in Europe's pharma industry is heating up, with the European Court of Justice's decision on Teva underlining the importance of getting communication and patent strategies right. MENA-based companies looking to enter the market will benefit from paying close attention.
For European #biopharma companies, the Middle East represents a new horizon.
Getting this expansion right will depend on your ability to adapt, not just to MENA's unique regulatory environment, but also to it's local norms and dynamics.
#MarketEntry #GlobalExpansion
Getting this expansion right will depend on your ability to adapt, not just to MENA's unique regulatory environment, but also to it's local norms and dynamics.
#MarketEntry #GlobalExpansion
AIM presents guide for biopharma expansion into the GCC region
For biopharma companies looking to grow, international expansion is key.
www.consultancy-me.com
October 3, 2025 at 9:00 AM
For European #biopharma companies, the Middle East represents a new horizon.
Getting this expansion right will depend on your ability to adapt, not just to MENA's unique regulatory environment, but also to it's local norms and dynamics.
#MarketEntry #GlobalExpansion
Getting this expansion right will depend on your ability to adapt, not just to MENA's unique regulatory environment, but also to it's local norms and dynamics.
#MarketEntry #GlobalExpansion
#OralSolidDosage manufacturing is complicated.
But instead of turning to other #DosageForms, manufacturers are enlisting the help of #CDMOs—and it's starting to pay off.
Source: https://uk.finance.yahoo.com/news/oral-solid-dosage-manufacturing-market-081500236.html
#Pharma
But instead of turning to other #DosageForms, manufacturers are enlisting the help of #CDMOs—and it's starting to pay off.
Source: https://uk.finance.yahoo.com/news/oral-solid-dosage-manufacturing-market-081500236.html
#Pharma
October 1, 2025 at 5:56 AM
#OralSolidDosage manufacturing is complicated.
But instead of turning to other #DosageForms, manufacturers are enlisting the help of #CDMOs—and it's starting to pay off.
Source: https://uk.finance.yahoo.com/news/oral-solid-dosage-manufacturing-market-081500236.html
#Pharma
But instead of turning to other #DosageForms, manufacturers are enlisting the help of #CDMOs—and it's starting to pay off.
Source: https://uk.finance.yahoo.com/news/oral-solid-dosage-manufacturing-market-081500236.html
#Pharma
Slow and steady wins the race.
As #OralSolids manufacturers prioritize speed to clinic, they can't afford to forget the importance of front-loaded #RiskIdentification. The earlier you spot a compound's red flags, the easier it is to work around them.
#DrugDevelopment
As #OralSolids manufacturers prioritize speed to clinic, they can't afford to forget the importance of front-loaded #RiskIdentification. The earlier you spot a compound's red flags, the easier it is to work around them.
#DrugDevelopment
September 29, 2025 at 7:57 AM
Slow and steady wins the race.
As #OralSolids manufacturers prioritize speed to clinic, they can't afford to forget the importance of front-loaded #RiskIdentification. The earlier you spot a compound's red flags, the easier it is to work around them.
#DrugDevelopment
As #OralSolids manufacturers prioritize speed to clinic, they can't afford to forget the importance of front-loaded #RiskIdentification. The earlier you spot a compound's red flags, the easier it is to work around them.
#DrugDevelopment
Planning to hand over your high-potent #OraldSolidDose manufacturing to a #CDMO?
There are a few steps you need to take to make sure everything goes smoothly, starting with establishing a robust project management framework.
#Pharmaceuticals #Manufacturing
There are a few steps you need to take to make sure everything goes smoothly, starting with establishing a robust project management framework.
#Pharmaceuticals #Manufacturing
Six Essential Steps Identified for Transferring High-Potent Oral Solid Dose Drug Manufacturing to CDMOs - GeneOnline News
A recent analysis highlights six critical steps for suc […]
www.geneonline.com
September 26, 2025 at 8:00 AM
Planning to hand over your high-potent #OraldSolidDose manufacturing to a #CDMO?
There are a few steps you need to take to make sure everything goes smoothly, starting with establishing a robust project management framework.
#Pharmaceuticals #Manufacturing
There are a few steps you need to take to make sure everything goes smoothly, starting with establishing a robust project management framework.
#Pharmaceuticals #Manufacturing
How do you develop an #OralSolidDosage form for a poorly soluble drug?
Despite technological advancements, this challenge remains a key barrier in #DrugDevelopment. However, that could soon change. By using AI to identify potential formulations, we may be able to speed up the process.
#Pharma
Despite technological advancements, this challenge remains a key barrier in #DrugDevelopment. However, that could soon change. By using AI to identify potential formulations, we may be able to speed up the process.
#Pharma
September 24, 2025 at 6:53 AM
How do you develop an #OralSolidDosage form for a poorly soluble drug?
Despite technological advancements, this challenge remains a key barrier in #DrugDevelopment. However, that could soon change. By using AI to identify potential formulations, we may be able to speed up the process.
#Pharma
Despite technological advancements, this challenge remains a key barrier in #DrugDevelopment. However, that could soon change. By using AI to identify potential formulations, we may be able to speed up the process.
#Pharma
#DrugManufacturers in Europe shouldn't overlook the value of entering the MENA market.
By commercializing 3 #biosimilars in the region, Polpharma Biologics is tapping into an underutilized market and bringing better MS treatment to everyone.
#Pharmaceuticals
By commercializing 3 #biosimilars in the region, Polpharma Biologics is tapping into an underutilized market and bringing better MS treatment to everyone.
#Pharmaceuticals
Partnership to bring Ocrevus biosimilar drug for MS to MENA region
A new partnership will bring three new medications to the Middle East and North Africa, including an Ocrevus biosimilar drug for MS patients.
multiplesclerosisnewstoday.com
September 22, 2025 at 9:01 AM
#DrugManufacturers in Europe shouldn't overlook the value of entering the MENA market.
By commercializing 3 #biosimilars in the region, Polpharma Biologics is tapping into an underutilized market and bringing better MS treatment to everyone.
#Pharmaceuticals
By commercializing 3 #biosimilars in the region, Polpharma Biologics is tapping into an underutilized market and bringing better MS treatment to everyone.
#Pharmaceuticals
The global #pharma market is set to grow at a CAGR of 7.7% until 2033, making this an excellent time for companies to invest in their own growth.
For companies looking to expand into new markets, #Europe offers a stable and resilient market thanks to its mature health systems.
#GlobalStrategy
For companies looking to expand into new markets, #Europe offers a stable and resilient market thanks to its mature health systems.
#GlobalStrategy
September 19, 2025 at 8:08 AM
The global #pharma market is set to grow at a CAGR of 7.7% until 2033, making this an excellent time for companies to invest in their own growth.
For companies looking to expand into new markets, #Europe offers a stable and resilient market thanks to its mature health systems.
#GlobalStrategy
For companies looking to expand into new markets, #Europe offers a stable and resilient market thanks to its mature health systems.
#GlobalStrategy
Highly potent APIs don't come without risk. The need to avoid operator exposure and environmental and cross-contamination when handling these ingredients is only making #OralSolidDosage manufacturing more difficult.
Could investing in AI and IoT-powered contamination control be the solution?
Could investing in AI and IoT-powered contamination control be the solution?
September 17, 2025 at 9:01 AM
Highly potent APIs don't come without risk. The need to avoid operator exposure and environmental and cross-contamination when handling these ingredients is only making #OralSolidDosage manufacturing more difficult.
Could investing in AI and IoT-powered contamination control be the solution?
Could investing in AI and IoT-powered contamination control be the solution?